A Randomized Controlled Trial to Promote Physician-Patient Discussion of Prostate Cancer Screening
NCT00208988 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250
Last updated 2005-09-21
Summary
Prostate cancer is the most common type of cancer among men. It is also the second leading cause of cancer-related death among men. Two screening tests are available to try to detect prostate cancer early - the digital rectal examination (DRE) and the prostate specific antigen (PSA) blood test. Unfortunately, physicians aren't sure whether or not these two screening tests help save lives, and there's a lot of controversy about how to use them. Recently, a major government committee (the U.S. Preventive Services Task Force) recommended that physicians discuss the risks and potential benefits of prostate cancer screening with their patients, and allow patients to make their own decision.
Because of the controversies, many physicians currently don't discuss prostate cancer with their patients. The problem is that it takes time and effort to have these discussions, and the information is complicated. A lot of patients have trouble understanding it, especially if they have a limited educational background or trouble reading. When patients have difficulty obtaining, understanding, and acting on basic health information, we say that they have "low health literacy." Other researchers have shown that patients with low health literacy don't know as much about cancer screening and are less likely to get screened for various cancers. They also tend to be timid about discussing things with their doctor, and often go along with what the doctor says, rather than taking an active role in the decision making.
In 2003, under IRB approval, we conducted a study with 2 goals: 1) to encourage patients to talk to their doctor about prostate cancer screening, and 2) to learn more about the impact of low health literacy on these conversations. To promote conversation, we used two handouts, given to patients in the waiting room before they saw the doctor. The first was a patient education handout about prostate cancer screening, written in very simple terms with useful illustrations. The second was a handout that simply encouraged patients to talk to their doctor about prostate cancer. Patients got one of the two handouts, or a nutritional handout that served as a control. After they saw their doctor, a research assistant briefly interviewed the patient to find out whether or not prostate cancer screening was discussed. We also measured the patients' health literacy skills, and asked a few other questions about their decision to get screened for prostate cancer.
Conditions
Interventions
- PROCEDURE
-
Educational handout about prostate cancer screening
- PROCEDURE
-
Simple cue for patient to talk to doctor
Sponsors & Collaborators
-
Emory University
lead OTHER
Principal Investigators
-
Sunil Kripalani, MD, MSc · Emory University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- ECT
- Masking
- SINGLE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 45 Years
- Max Age
- 70 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2003-05-31
- Completion
- 2003-08-31
Countries
- United States
Study Locations
More Related Trials
-
Prostate Cancer Screening Among Men With High Risk Genetic Predisposition
NCT02053805 ·Status: UNKNOWN ·Phase: NA
-
Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)
NCT03328091 ·Status: COMPLETED ·Phase: NA
-
Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform
NCT04100811 ·Status: ACTIVE_NOT_RECRUITING
-
Addressing Health Literacy With a Tailored Survivorship Care Plan
NCT06674863 ·Status: RECRUITING ·Phase: NA
-
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
NCT01844999 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence
NCT02070575 ·Status: COMPLETED
-
Cilengitide in Treating Patients With Prostate Cancer
NCT00121238 ·Status: COMPLETED ·Phase: PHASE2
-
Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer
NCT04869371 ·Status: UNKNOWN ·Phase: PHASE2
-
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer
NCT02168062 ·Status: TERMINATED ·Phase: PHASE2
-
Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer
NCT02685267 ·Status: TERMINATED ·Phase: PHASE2
-
Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer
NCT02757365 ·Status: UNKNOWN ·Phase: PHASE4
-
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
NCT03298087 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
NCT03833921 ·Status: RECRUITING ·Phase: PHASE2
-
Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study
NCT04447703 ·Status: COMPLETED ·Phase: NA
-
Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly
NCT00161252 ·Status: WITHDRAWN
-
The Effect of the Prostate Cancer Foundation Screening Guidelines for Black Men on Intention to Screen in Faith-based Communities
NCT06838325 ·Status: COMPLETED ·Phase: NA
-
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
NCT00288080 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy
NCT00148772 ·Status: COMPLETED ·Phase: PHASE2
-
PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802
NCT01672905 ·Status: COMPLETED
-
Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer
NCT01748500 ·Status: COMPLETED ·Phase: PHASE2
-
Goals of Sexual Function in Prostate Cancer Survivors and Their Partners After Cancer Treatment
NCT01018901 ·Status: COMPLETED ·Phase: NA
-
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Surgery in Treating Patients With Prostate Cancer
NCT00002938 ·Status: COMPLETED ·Phase: PHASE2
-
Stockholm3 Validation Study in a Multi-Ethnic Cohort
NCT04583072 ·Status: COMPLETED
-
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
NCT06990880 ·Status: RECRUITING ·Phase: PHASE1/PHASE2